Lead Product(s): Sintilimab,Cotsiranib
Therapeutic Area: Oncology
Highest Development Status: Undisclosed Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 06, 2020
The firms have entered into a mutual partnership to perform clinical studies using Sirnaomics' RNAi drug candidate STP705 and Tyvyt by Innovent and , for combination treatment in advanced cancers.